Search Results

Cell therapy and oncology–focused Carisma Therapeutics started layoffs late last year. Now the company plans to wind down fully.

Carisma’s second workforce reduction this year likely leaves the company with 44 full-time employees as turns its focus to developing therapies for fibrosis, oncology and autoimmune diseases.

Carisma Therapeutics Inc. today announced that Steven Kelly , President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference.

Carisma Therapeutics Inc. today announced the appointment of Marella Thorell and David Scadden, M.D., to the Company’s Board of Directors, effective June 30, 2024.

Carisma Therapeutics Inc. today announced that Steven Kelly , President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Cell Therapy Forum on Tuesday, July 9th at 9:10 am ET.

Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of the first development candidate (“Development Candidate”), under its collaboration with Moderna, Inc.

Carisma Therapeutics Inc. today announced the appointment of John Hohneker, M.D. to the Board of Directors.

Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended March 31, 2024, and highlighted recent business updates.

Carisma Therapeutics Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that it will present at the following upcoming conferences.

Carisma Therapeutics Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that the Company’s virtual annual meeting of stockholders held on June 13, 2024 was convened and adjourned, without any business being conducted, due to technical difficulties with the third-party hosting site.